FilingReader Intelligence
Fosun Pharma subsidiary gets cancer drug application accepted
August 12, 2025 at 05:00 PM UTC•By FilingReader AI
Jisimei (Wuhan) Pharmaceutical, a Shanghai Fosun Pharmaceutical subsidiary, had its Nedaplatin for Injection drug registration application accepted by the National Medical Products Administration.
The cancer treatment generated approximately RMB353 million in China sales in 2024, according to IQVIA data. Commercial production remains subject to final drug registration approval.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:2196•Hong Kong Exchange
News Alerts
Get instant email alerts when Shanghai Fosun Pharmaceutical (Group) Co publishes news
Free account required • Unsubscribe anytime